- If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license - - Stealth to receive initial payment of ...

NEEDHAM, Mass., March 13, 2025 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biopharmaceutical company focused on the discovery, development and ...

Please provide your email address to receive an email when new articles are posted on . According to McCarthy, as an investigational agent, elamipretide is formulated to be an at-home once-daily ...

FDA advisors indicated a possible path forward for elamipretide as a treatment for Barth syndrome despite the lack of definitive evidence. On Thursday, the Cardiovascular and Renal Drugs Advisory ...

NEW YORK (WABC) -- People with Barth Syndrome - an ultra-rare, life-threatening disease - and parents of children with it are pushing the Federal Drug Administration merely to review an application ...

The Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for elamipretide in the treatment of Barth syndrome, a rare mitochondrial disease.

BOSTON, May 29, 2025--(BUSINESS WIRE)--The Barth Syndrome Foundation (BSF) today responded to new developments from the U.S. Food and Drug Administration (FDA) regarding elamipretide, a potential ...

Credit: Shutterstock. Elamipretide has been shown to improve frataxin levels in Friedreich ataxia patient-derived cells, and improve motor and cardiac function in an animal model of Friedreich ataxia.

"We appreciate the FDA's timely acceptance and commitment to expeditiously review our NDA resubmission," said Reenie McCarthy, Chief Executive Officer. "We are sharing this news in the spirit of ...

BOSTON, April 30, 2018 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, announced that the U.S.

Another ultra-rare therapy will soon be subject to the gaze of an FDA advisory committee, with the fate of more than 200 boys diagnosed with Barth syndrome worldwide in the balance. On Thursday, the ...

Please provide your email address to receive an email when new articles are posted on . NEW YORK — Reduction of progressive ellipsoid zone attenuation through the use of subcutaneous elamipretide may ...